B. Riley Securities Maintains Buy on TG Therapeutics, Raises Price Target to $86
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
B. Riley Securities analyst William Woods maintains TG Therapeutics (NASDAQ:TGTX) with a Buy and raises the price target from $55 to $86.
B. Riley Securities analyst William Woods maintains TG Therapeutics (NASDAQ:TGTX) with a Buy and raises the price target from $55 to $86.